| A208 |
Figitumumab Biosimilar（Anti-IGF1R / CD221 Reference Antibody）
Featured
|
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM. |
.png)
|
| A209 |
Dalotuzumab Biosimilar（Anti-IGF1R / CD221 Reference Antibody）
Featured
|
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo. |
.png)
|
| A210 |
Cixutumumab Biosimilar（Anti-IGF1R / CD221 Reference Antibody）
Featured
|
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer. |
.png)
|
| A211 |
Immunomedics patent anti-IGF-1R Biosimilar（Anti-IGF1R / CD221 Reference Antibody）
Featured
|
|
|
| A212 |
DX-2647 Biosimilar（Anti-IGF-2 Reference Antibody）
Featured
|
|
|
| A213 |
BT-063 Biosimilar（Anti-IL-10 Reference Antibody）
Featured
|
|
|
| A214 |
Ebdarokimab Biosimilar（Anti-IL-12b Reference Antibody）
Featured
|
Ebdarokimab (AK101) is a humanized IgG1-κ antibody, usually expressed in CHO (Chinese Hamster Ovary) cells. |
.png)
|
| A215 |
Lebrikizumab Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
Lebrikizumab is an IgG4 humanized monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its function. Lebrikizumab can be used for the research of asthma. |
.png)
|
| A217 |
IMA-026 Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
|
|
| A218 |
GSK 679586 Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
|
|
| A219 |
Abrezekimab Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma. |
.png)
|
| A220 |
Cendakimab Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis). |
.png)
|
| A221 |
Dectrekumab Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research. |
.png)
|
| A222 |
CNTO 607 Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
|
|
| A223 |
Tralokinumab Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD). |
.png)
|
| A224 |
H2L6 Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
|
|
| A225 |
M1295 Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
|
|
| A226 |
Eblasakimab Biosimilar（Anti-IL-13Ra1 / CD213a1 Reference Antibody）
Featured
|
|
|
| A227 |
Wake Forest U. patent anti-IL-13RA2 Biosimilar（Anti-IL-13Ra2 / CD213a2 Reference Antibody）
Featured
|
|
|
| A228 |
Ordesekimab Biosimilar（Anti-IL-15 Reference Antibody）
Featured
|
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD). |
.png)
|
| A229 |
DISC0280 Biosimilar（Anti-IL-15 Reference Antibody）
Featured
|
|
|
| A230 |
Brodalumab Biosimilar（Anti-IL-17Ra / CD217 Reference Antibody）
Featured
|
Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis. |
|
| A231 |
GSK 1070806 Biosimilar（Anti-IL-18 Reference Antibody）
Featured
|
|
|
| A232 |
ABT-325 Biosimilar（Anti-IL-18 Reference Antibody）
Featured
|
|
|
| A233 |
Gevokizumab Biosimilar（Anti-IL-1b Reference Antibody）
Featured
|
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II). |
.png)
|
| A235 |
Canakinumab Biosimilar（Anti-IL-1b Reference Antibody）
Featured
|
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin. |
.png)
|
| A236 |
AMG 108 Biosimilar（Anti-IL-1R1 / CD121a Reference Antibody）
Featured
|
|
|
| A237 |
Nidanilimab Biosimilar（Anti-IL-1RAP / IL-1R3 Reference Antibody）
Featured
|
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) . |
.png)
|
| A238 |
Melrilimab Biosimilar（Anti-IL-1RL1 / ST2 / IL-33R Reference Antibody）
Featured
|
Melrilimab (GSK 3772847) is an IgG2-kappa anti-IL1RL1/ST2/IL33R/DER4/FIT-1 monoclonal antibody. Melrilimab can be used for the research of asthma. |
.png)
|
| A239 |
Astegolimab Biosimilar（Anti-IL-1RL1 / ST2 / IL-33R Reference Antibody）
Featured
|
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. Astegolimab has the potential for chronic obstructive pulmonary disease (COPD) research. |
.png)
|
